Overview

Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
A Phase 1, Partially-Blinded, Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Include A Single Dose Food-Effect Study to Evaluate the Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects
Phase:
Phase 1
Details
Lead Sponsor:
Global Alliance for TB Drug Development